PetVivo Just Paid $75K to Exit Its PRP Deal. If You Stock Regenerative Therapies, Read This.

You're looking at your regenerative medicine set, the PRP kits, the stem cell adjacents, the high-ticket joint therapies vets refer clients to buy from you, and deciding whether to expand it or pull back.

PetVivo Holdings just terminated its exclusive license with VetStem for the PrecisePRP product line, paid $75,000 to settle all obligations under the prior agreement, and is returning remaining inventory to VetStem. The company announced the termination and settlement agreement effective July 24, 2026.

What PetVivo actually just did

PetVivo and VetStem had an Exclusive License and Supply Agreement covering PrecisePRP, a platelet-rich plasma product line used in veterinary regenerative medicine. Under the settlement, that agreement is terminated. All financial obligations under the prior license, outstanding invoices, accrued royalties, milestone payments, other claims, are extinguished except for two scheduled cash payments totaling $75,000. The companies included mutual releases for substantially all claims arising under the prior agreement.

The settlement also includes an inventory reconciliation mechanism. If the transferred inventory falls short of agreed minimum quantities after verification, PetVivo may owe an additional payment. The remaining PrecisePRP inventory goes back to VetStem. A warrant VetStem holds to purchase 250,000 shares of PetVivo common stock stays in force under its existing terms.

PetVivo's CEO John Lai said the agreement "allows both companies to move forward independently" and lets PetVivo focus on its proprietary technologies, including SPRYNG with OsteoCushion Technology.

If you currently stock PrecisePRP

Call your rep and ask three things: whether existing inventory on your shelf is still supported under warranty, whether VetStem will continue the PrecisePRP line under its own distribution, and what happens to any vet referral arrangements you built around the product. The settlement says inventory is going back to VetStem, which suggests VetStem may relaunch it independently or retire it, you need to know which before a customer walks in with a vet's recommendation.

If you're holding significant inventory and the line is being retired, negotiate a return now while the settlement is fresh. If VetStem is relaunching it, decide whether you reorder through a new channel or use the transition to test a competing product. The regenerative category is high-margin but also high-education, switching products mid-relationship with a referring vet practice is friction you want to avoid unless the economics force it.

If your week runs on calls like this one, subscribe to PetRetailNews.

If you were planning to add regenerative therapies

This settlement is a reminder that emerging biomedical categories carry supplier risk. PetVivo is a publicly traded company with multiple subsidiaries and a stated focus on "innovative medical devices and therapeutics for horses and companion animals," but it just paid to exit a product line and hand back inventory. That is not inherently bad, companies refocus, but it does mean the category is still consolidating and not every product you stock today will have the same supplier backing it in 18 months.

Before you commit shelf space and staff training to any regenerative product, ask the supplier: How long has this SKU been in market? How many independent retailers carry it? What happens to my inventory if you pivot? The answers tell you whether you are betting on a proven line or subsidizing someone's product-market fit experiment.

The failure mode if you read this wrong

The mistake is treating this as a PetVivo story when it is actually a category-maturity story. Regenerative medicine for pets is real, the science works, and the margin is there, but the supplier landscape is not settled. If you stock one brand because a rep sold you on the category's growth and that brand exits or restructures, you are left explaining to a customer why the product their vet recommended is no longer on your shelf. That is a trust cost, and in a high-ticket category built on referrals, trust is the entire moat.

The play is not to avoid the category. The play is to stock it with your eyes open: know who actually manufactures the product, know whether the brand has been around long enough to survive a bad quarter, and have a backup supplier relationship started before you need it. PetVivo is now focusing on SPRYNG and its other proprietary lines. VetStem may or may not continue PrecisePRP independently. Either way, if you built your regenerative set around this partnership, you have work to do.

← Back to the Newsdesk